What is RAND's health score?

As of October 24, 2026, TradeApes rates RAND CAPITAL CORP (RAND) 49 out of 100 (Mixed); valuation verdict: Inconclusive. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is RAND's estimated fair value?

Our methods couldn't reach a reliable fair value for RAND yet. This is a model assessment, not a price target or investment recommendation.

Is RAND undervalued or overvalued?

Our model currently rates RAND as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

📱 Now on iPhone — live scores, valuations & alerts on the go

Download iPhone App

RAND CAPITAL CORP (RAND)

Name: TradeApes health score and valuation for RAND CAPITAL CORP (RAND)
Creator: TradeApes
License: https://www.tradeapes.com/terms.html

Inconclusive inconclusive mixed

$9.5

Updated: 2026-10-24

Next earnings: Nov 4, before open (est.)

As of October 24, 2026, TradeApes rates RAND CAPITAL CORP (RAND) 49 out of 100 (Mixed); valuation verdict: Inconclusive.

TradeApes Score

Financial Strength

45 Mixed

Operating Trend

50 Mixed

Relative Value

40 Overvalued

Capital Allocation

50 Mixed

Risk Management

80 Strong

Our methods couldn't reach a reliable fair value for RAND yet.

Key Findings

What to watch

− Low FCF yield — below 1%, price implies exceptional future growth
− Piotroski F-Score 0–3 — multiple financial weakness signals

See every signal behind RAND's score →

AI-written analysis

The full RAND CAPITAL CORP (RAND) analysis

Why the model reads RAND as inconclusive, the methods that voted, and what would change the verdict. Written from the same filings as the score above. How these are written

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.